Patient‐reported outcomes and quality of life in dominant dystrophic epidermolysis bullosa: A global cross‐sectional survey-Reference-Cited by-同舟云学术

Patient‐reported outcomes and quality of life in dominant dystrophic epidermolysis bullosa: A global cross‐sectional survey

Published:2021-09 Issue:5 Volume:38 Page:1198-1201
ISSN:0736-8046
Container-title:Pediatric Dermatology
language:en
Short-container-title:Pediatr Dermatol

Author:

Fulchand Shivali¹^ORCID,Harris Nicole¹,Li Shufeng¹,Barriga Melissa¹,Gorell Emily²^ORCID,De Souza Mark³,Murrell Dedee⁴^ORCID,Marinkovich M. Peter¹⁵,Krishna Yenamandra Vamsi⁶,Tang Jean Y.¹

Affiliation:

1. Department of Dermatology Stanford University School of Medicine Stanford CA USA

2. Department of Dermatology University of Cincinnati College of Medicine Cincinnati OH USA

3. deSouzaTech, LLC Berkeley CA USA

4. The George Institute of Global Health University of New South Wales Sydney NSW Australia

5. Veterans Affairs Medical Center Palo Alto CA USA

6. Skin & Epithelial Cell Biology Unit CSIR‐Institute of Genomics & Integrative Biology New Delhi India

Funder

Epidermolysis Bullosa Medical Research Foundation

Publisher

Wiley

Subject

Dermatology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/pde.14802

Reference5 articles.

1. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility

2. QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study

3. Patient‐reported outcomes and quality of life in recessive dystrophic epidermolysis bullosa: a global cross‐sectional survey;Eng VA;J Am Acad Dermatol,2020

4. Biology of anchoring fibrils: lessons from dystrophic epidermolysis bullosa

5. Assessment of the Timing of Milestone Clinical Events in Patients With Epidermolysis Bullosa From North America

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A scalable and cGMP-compatible autologous organotypic cell therapy for Dystrophic Epidermolysis Bullosa;Nature Communications;2024-07-11

2. Practical considerations relevant to treatment with the gene therapy beremagene geperpavec-svdt for dystrophic epidermolysis bullosa;Journal of Dermatological Treatment;2024-05-09

3. Natural History Study of Recessive Dystrophic Epidermolysis Bullosa Wounds and Patient Reported Outcomes Using Mobile Application Home Photography;2024-03-26

4. Management of Skin Lesions in Patients with Epidermolysis Bullosa by Topical Treatment: Systematic Review and Meta-Analysis;Healthcare;2024-01-19

5. Type VII Collagen Deficiency in the Oncogenesis of Cutaneous Squamous Cell Carcinoma in Dystrophic Epidermolysis Bullosa;Journal of Investigative Dermatology;2023-11